Inhoudsopgave:
|
Now fully revised to include recent advances in the field, the second edition of\u003ci\u003e Bone and Soft Tissue Pathology\u003c/i\u003e, a volume in the Foundations in Diagnostic Pathology series, is an essential foundation text for residents and pathologists. The \u003cb\u003epopular template format\u003c/b\u003e makes it easy to use, and new information throughout brings you up to date with whatâs new in the field, including advances in molecular diagnostic testing and new diagnostic biomarkers. Practical and affordable, this resource is \u003cb\u003eideal for study and review as well as everyday clinical practice.\u003c/b\u003e\u003cp\u003e\u003cb\u003e\u003ci\u003eKey features of this practical text include:\u003c/i\u003e\u003c/b\u003e \u003c/p\u003e \u003cul\u003e \u003cli\u003eA \u003cb\u003econsistent, user-friendly format\u003c/b\u003e that explores each entity's clinical features, pathologic features (gross and microscopic), ancillary studies, differential diagnoses, and prognostic and therapeutic considerations. \u003c/li\u003e \u003cli\u003eA \u003cb\u003efocus on specific features\u003c/b\u003e of selected neoplastic and non-neoplastic entities, including broad and in-depth differential diagnoses. \u003c/li\u003e \u003cli\u003eReview of normal histology before examining abnormal findings, enabling you to conveniently \u003cb\u003ecompare their characteristics\u003c/b\u003e in one place at one time. \u003c/li\u003e \u003cli\u003e\u003cb\u003eClinical information\u003c/b\u003e on treatment and prognosis, enabling you to better understand the clinical implications of the diagnosis. \u003c/li\u003e \u003cli\u003eNearly \u003cb\u003e1,000 full-color, high-quality illustrations\u003c/b\u003e with extensive figure legends, as well as \u003cb\u003eabundant boxes and tables\u003c/b\u003e throughout. \u003c/li\u003e\u003c/ul\u003e \u003cp\u003e\u003cb\u003e\u003ci\u003eWhatâs NEW in this edition:\u003c/i\u003e\u003c/b\u003e \u003c/p\u003e \u003cul\u003e \u003cli\u003eAdvances in \u003cb\u003emolecular diagnostic testing\u003c/b\u003e and its capabilities and limitations, including targeted/personalized medicine. \u003c/li\u003e \u003cli\u003eNew \u003cb\u003ediagnostic biomarkers\u003c/b\u003e and their utility in differential diagnosis, newly described variants, and new histologic entities. \u003c/li\u003e \u003cli\u003eThe latest TNM staging and WHO classification systems. \u003c/li\u003e \u003cli\u003eNew co-editor Dr. Gunnlaugur Pétur Nielsen of Harvard Medical School joins Dr. Andrew L. Folpe and \u003cb\u003eexpert, internationally recognized pathologists\u003c/b\u003e who keep you up to date with the latest information in the field.\u003c/li\u003e\u003c/ul\u003e |
nl
en